DELRAY
BEACH, Fla., Sept. 11,
2024 /PRNewswire/ -- The cell-based assays market is
expected to grow from USD 17.3
billion in 2024 to USD 24.3
billion by 2029, reflecting a compound annual growth rate
(CAGR) of 7.1%. This growth is driven by increasing demand for drug
discovery and development, heightened preference for cell-based
assays over animal studies, government funding for cell-based
research, and rising cancer prevalence. Strategic alliances and
growing applications in chronic diseases and personalized medicine
are also expected to support market expansion. However, the high
cost of instruments and licensing restrictions for reagents may
hinder growth. Key drivers include growing government support and
investments in advanced therapeutics, exemplified by a recent grant
from the National Research Fund to KEMRI. Challenges involve the
complexities in assay design and high costs of advanced
technologies. The consumables segment led the market in 2023, while
North America held the largest
market share, followed by Europe
and the Asia Pacific. Key players
include BD, Thermo Fisher Scientific, Danaher Corporation, and
Merck KGaA, among others. Recent developments include new product
launches and strategic acquisitions aimed at enhancing assay
capabilities and expanding research automation.
Download PDF Brochure:
https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=119917269
Browse in-depth TOC on "Cell-Based Assays
Market"
200 - Tables
50 - Figures
350 -
Pages
Market Segmentation by Offering
The global cell-based assays market is categorized into
consumables, instruments, software, and services. Among these, the
services segment is projected to experience the highest CAGR during
the forecast period. Increasingly, researchers and pharmaceutical
companies are outsourcing aspects of their cell-based assays to
specialized service providers. These providers offer expertise,
infrastructure, and streamlined processes that save time and
resources. Comprehensive service packages, including assay
development, screening, data analysis, and quality control, enable
researchers to focus on core activities, thus accelerating drug
discovery and development. This growing demand for services is
driving market growth.
Market Segmentation by Technology
The cell-based assays market is divided into flow cytometry,
high throughput screening, label-free detection, and other
technologies. In 2023, the flow cytometry segment held the largest
share of the market. The segment's growth is attributed to the
extensive use of flow cytometry in cell-based research.
Additionally, the rising demand for drug discovery and advanced
cell-based therapies, driven by the increasing prevalence of
chronic diseases, is expected to further boost the segment's
growth.
Market Segmentation by Application
The cell-based assays market is segmented into drug discovery,
basic research, genetic research, and other applications. The drug
discovery segment is further divided into toxicology,
pharmacodynamics, and pharmacokinetics. In 2023, drug discovery was
the dominant segment in the cell-based assays market. This
dominance is driven by recent advancements in cell-based assays and
the growing adoption of 3D cultures and automated cell analysis
systems for high-throughput screening. Increasing funding and
investments in cell-based research, new drug introductions, and the
rising number of contract research organizations (CROs) offering
drug discovery services are also contributing to market growth.
Market Segmentation by End User
The cell-based assays market is divided into pharmaceutical
& biopharmaceutical companies, contract research organizations
(CROs), and academic & research institutes. In 2023,
pharmaceutical & biopharmaceutical companies held the largest
market share. This growth is due to the increased focus on
developing advanced cell-based therapies and the expansion of
biopharmaceutical companies. Additionally, growing investments in
R&D are likely to support continued market growth.
Regional Market Analysis
Key regional markets for cell-based assays include North America, Europe, Asia
Pacific, Latin America, the
Middle East, and Africa. North
America held the largest market share in 2023, thanks to its
emphasis on advanced cell-based therapies and healthcare
infrastructure advancements. However, the Asia Pacific region is expected to exhibit the
highest CAGR during the forecast period. Growth in this region is
driven by increasing research practices in biotechnology and life
sciences, as well as a growing focus on advancing the
biopharmaceutical industry.
Request Sample Pages:
https://www.marketsandmarkets.com/requestsampleNew.asp?id=119917269
Competitive Landscape
The global cell-based assays market is highly competitive,
featuring major players such as Danaher Corporation (US), Thermo
Fisher Scientific Inc. (US), Merck KGaA (Germany), BD (US), Agilent Technologies, Inc.
(US), Lonza (Switzerland), and
Eurofins Scientific (Luxembourg).
These companies employ various strategies, including new product
launches, acquisitions, agreements, collaborations, and
geographical expansions, to enhance their market positions.
Danaher Corporation (US)
Danaher Corporation is a prominent innovator in life sciences
and diagnostics, offering a wide range of products and services for
medical, industrial, and commercial use. With a strong global
presence, Danaher emphasizes strategic alliances to expand its
reach. For example, in October 2023,
Danaher's Beckman Coulter Life Sciences partnered with 10x Genomics
to enhance automation solutions for single-cell assay workflows.
Additionally, Danaher is expanding its facilities; in May 2022, Cytiva opened a new manufacturing site
in Grens, Switzerland, to produce
single-use kits for cell processing and consumables for cell
expansion systems.
Thermo Fisher Scientific Inc. (US)
Thermo Fisher Scientific is a leading company in science and
technology, specializing in high-end analytical instruments,
laboratory equipment, software, consumables, reagents, and services
for scientific research, analysis, discovery, and diagnostics.
Operating in over 180 countries, Thermo
Fisher is focused on strengthening its global footprint
through strategic alliances. Notably, in February 2021, the company acquired cell sorting
technology assets from Propel Labs to bolster its capabilities.
Merck KGaA (Germany)
Merck KGaA provides comprehensive solutions and services for
research, biotechnology, and pharmaceutical drug development. The
company offers tools, services, and digital platforms to support
researchers across various fields. With a solid customer base
globally, Merck KGaA continues to invest in research and
development to enhance its product offerings and global presence.
For example, in March 2021, Merck
invested USD 30.4 million in a new
single-use assembly production unit at its Life Science Center in
Molsheim, France, aiming to
increase production capacity for COVID-19 vaccines and other
critical therapies.
For more information, Inquire Now!
Related Reports:
Cell Expansion Market
Cell Isolation Market
3D Cell Culture Market
Immunoassay Market
Multiplex Assays Market
Get access to the latest updates on Cell Based Assays
Companies and Cell Based Assays Market Share
About MarketsandMarkets™:
MarketsandMarkets™ has been recognized as one of America's
best management consulting firms by Forbes, as per their recent
report.
MarketsandMarkets™ is a blue ocean alternative in growth
consulting and program management, leveraging a man-machine
offering to drive supernormal growth for progressive organizations
in the B2B space. We have the widest lens on emerging technologies,
making us proficient in co-creating supernormal growth for
clients.
Earlier this year, we made a formal transformation into one of
America's best management consulting firms as per a survey
conducted by Forbes.
The B2B economy is witnessing the emergence of $25 trillion of new revenue streams that are
substituting existing revenue streams in this decade alone. We work
with clients on growth programs, helping them monetize this
$25 trillion opportunity through our
service lines - TAM Expansion, Go-to-Market (GTM) Strategy to
Execution, Market Share Gain, Account Enablement, and Thought
Leadership Marketing.
Built on the 'GIVE Growth' principle, we work with several
Forbes Global 2000 B2B companies - helping them stay relevant in a
disruptive ecosystem. Our insights and strategies are molded by our
industry experts, cutting-edge AI-powered Market Intelligence
Cloud, and years of research. The KnowledgeStore™ (our Market
Intelligence Cloud) integrates our research, facilitates an
analysis of interconnections through a set of applications, helping
clients look at the entire ecosystem and understand the revenue
shifts happening in their industry.
To find out more, visit www.MarketsandMarkets™.com or follow us
on Twitter, LinkedIn and Facebook.
Contact:
Mr. Rohan
Salgarkar
MarketsandMarkets™ INC.
1615 South Congress Ave.
Suite 103, Delray Beach, FL
33445
USA: +1-888-600-6441
Email: sales@marketsandmarkets.com
Visit Our Website: https://www.marketsandmarkets.com/
Logo:
https://mma.prnewswire.com/media/1951202/4609423/MarketsandMarkets.jpg
View original
content:https://www.prnewswire.com/news-releases/cell-based-assays-market-to-grow-from-usd-17-3b-in-2024-to-usd-24-3b-by-2029-at-7-1-cagr--marketsandmarkets-302244849.html
SOURCE MarketsandMarkets